No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
TLSI TriSalus Life Sciences
- 7.900
- +0.340+4.50%
Close May 28 16:00 ET
214.56MMarket Cap-3297P/E (TTM)
7.900High7.570Low105.59KVolume7.780Open7.560Pre Close825.28KTurnover0.63%Turnover RatioLossP/E (Static)27.16MShares16.24052wk High-6.14P/B131.80MFloat Cap3.32052wk Low--Dividend TTM16.68MShs Float16.240Historical High--Div YieldTTM4.37%Amplitude3.320Historical Low7.815Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
LIDR, HOOK and BCAB Among Mid-day Movers
12 Health Care Stocks Moving In Friday's Intraday Session
GainersInnovative Eyewear (NASDAQ:LUCY) shares increased by 328.8% to $0.8 during Friday's regular session. The market value of their outstanding shares is at $13.9 million. OneMedNet (NASDAQ:ONMD) sh
Nasdaq Gains 1%; Intuit Shares Plunge
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 1% on Friday.The Dow traded up 0.25% to 39,163.18 while the NASDAQ rose 1.04% to 16,909.33. The S&P 500 also
Express News | TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants
JonesTrading Sticks to Their Buy Rating for TriSalus Life Sciences (TLSI)
Navigating the Financial Tightrope: Trisalus Life Sciences' High-Stakes Debt Strategy With OrbiMed
Comments
$TriSalus Life Sciences(TLSI.US$ TriSalus Life Sciences Inc: Full Year Sales Growth Expected to Exceed 50%
$TriSalus Life Sciences(TLSI.US$ TriSalus Life Sciences Announces CMS Reimbursement for the TriNav Infusion System via Assignment of a New Technology Healthcare Common Procedure Coding System (HCPCS) Code![]()
5
15
$TriSalus Life Sciences(TLSI.US$ Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications Via BusinessWire TLSI Share – New data from PERIO-01 clinical trial indicates PEDD™ method resulted in modulation of the tumor microenvironment by enabling performance of the TLR9 agonist, SD-101, in metastatic uveal melanoma, consistent with an earlier ...
2
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg